Pentadeca Arginate (PDA): A Stabilized BPC-157 Analog for Tissue Repair Research

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to pentadeca arginate (PDA) or BPC-157. Neither compound is FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

After the FDA classified BPC-157 as a Category 2 bulk drug substance in 2023, restricting its use in compounded medications, a new name began appearing on compounding pharmacy menus and wellness websites: "PDA peptide," short for pentadeca arginate. Vendors described it as a stabilized, legally compliant alternative to BPC-157, often claiming it was "1,000 times more stable at acidic pH." The framing implied a distinct, improved compound with its own research foundation.

The reality is more straightforward and worth understanding clearly. This article explains what pentadeca arginate is, how it relates to BPC-157, what the underlying preclinical research actually shows, and where the regulatory picture stands as of April 2026.

Key Takeaways

• Regulatory Status: As of April 2026, BPC-157 is classified as a Category 2 bulk drug substance by the FDA — prohibited in compounding under Section 503A and 503B. Pentadeca arginate (PDA) is not a separately classified compound but inherits this status as a variant of the same pentadecapeptide sequence.
• Research Stage: Preclinical only. A 2025 systematic review by Vasireddi and colleagues screened 544 papers and identified only one human study of BPC-157 — a 12-patient retrospective case series. No peer-reviewed study has ever investigated pentadeca arginate as a distinct molecule.
• Availability: Not legally marketed for human use. Superpower does not offer this substance. Products sold through online vendors as "research use only" are not regulated by the FDA.
• What it is: A 15-amino-acid synthetic peptide sharing the BPC-157 sequence (GEPPPGKPADDAGLV), marketed with an arginine salt counterion rather than an acetate salt. See the 2025 BPC-157 literature and patent review by Józwiak and colleagues in Pharmaceuticals (Basel) for the underlying chemistry.
• What the evidence actually shows: Extensive preclinical data in rodent models for BPC-157; no completed, published human efficacy trials; no separate PDA trial base as of April 2026.

Where PDA Comes From and How It Relates to BPC-157

Origin: BPC-157 is already a pentadecapeptide

The word "pentadecapeptide" is not a proprietary name. It is a structural description: a peptide chain of 15 amino acids. BPC-157 is, by definition, a pentadecapeptide. Its full amino acid sequence is GEPPPGKPADDAGLV. As a 2025 comprehensive review by Józwiak and colleagues in Pharmaceuticals (Basel) documents, BPC-157 was isolated from human gastric juice and has been studied in preclinical models since the early 1990s by a research group at the University of Zagreb. The compound does not exist as a stable free molecule in the body; it is a synthetic, stabilized fragment created for research purposes.

What "arginate" actually means

Peptides synthesized for research use are typically produced as salts, with a counterion attached to improve stability or solubility. BPC-157 is conventionally produced as an acetate salt (BPC-157 acetate). "Pentadeca arginate," or PDA, refers to the same GEPPPGKPADDAGLV peptide sequence produced with an arginine counterion — essentially a different salt form. The amino acid sequence of the peptide itself is unchanged.

Compounding pharmacy marketing materials have claimed this arginate counterion makes PDA "1,000 times more stable" than BPC-157 acetate at pH 3.0, the acidity of stomach acid. That specific stability claim has not been published in any peer-reviewed journal as of April 2026. It appears to originate from internal compounding vendor documentation, not independent laboratory research. Readers should treat it as an unverified marketing claim.

Why "PDA" entered the market when it did

In November 2023, the FDA added BPC-157 to its list of bulk drug substances that may present significant safety risks under Section 503A compounding. The agency's interim policy placed BPC-157 in Category 2, meaning it was prohibited from use in compounded medications pending further review. This removed a significant commercial pathway for compounding pharmacies that had been producing BPC-157 products.

The "PDA" rebranding emerged in the months following this classification. The argument made by some vendors was that because PDA uses an arginine counterion rather than acetate, it constitutes a distinct chemical entity not covered by the BPC-157 Category 2 ruling. Regulatory experts familiar with FDA compounding law, including those who interpret 503A bulk drug substance policy, have expressed significant skepticism about this argument. The FDA's classification addresses the peptide's amino acid sequence and biological activity, not merely its salt form. As of April 2026, no FDA guidance formally distinguishing PDA from BPC-157 has been issued.

What the Preclinical Research Actually Shows

Because PDA shares the BPC-157 sequence, its proposed biological activity is drawn entirely from the BPC-157 preclinical literature. That literature is substantial in volume and consistent in direction — but it has important limitations that are not always acknowledged in consumer-facing content.

Tissue repair and tendon healing

The most replicated preclinical findings for BPC-157 concern musculoskeletal soft tissue. A 2003 study by Staresinic, Sebecic, Patrlj, and colleagues in Journal of Orthopaedic Research used a rat Achilles tendon transection model with BPC-157 administered intraperitoneally once daily at 10 µg/kg, 10 ng/kg, or 10 pg/kg and reported improved load-to-failure, Young's modulus of elasticity, and Achilles functional index scores, reduced tendon defect size by day 14, and increased tendocyte outgrowth in vitro — with specific numerical effect sizes and p-values not reported in the abstract. A 2006 study by Krivic and colleagues in the same journal applied BPC-157 intraperitoneally once daily at 10 µg/kg, 10 ng/kg, or 10 pg/kg for 30 days to a rat Achilles-detachment model and reported that tendon-to-bone tissue, which did not heal spontaneously in saline controls, recovered with BPC-157 treatment, with directionally improved load-to-failure, stiffness, Young's modulus, and collagen organization at days 1–21, including in animals where healing had been impaired by 1 mg/kg 6α-methylprednisolone — though the abstract does not report numeric effect sizes or p-values. A 2010 study by Cerovecki and colleagues in Journal of Orthopaedic Research applied a similar protocol to medial collateral ligament transection in male Wistar rats — BPC-157 i.p. (10 µg or 10 ng/kg/day), topical (1.0 µg in cream), or per-oral (0.16 µg/mL in drinking water) over 90 days — and described directional improvements across biomechanical, functional, macroscopic, and histological endpoints, though specific effect sizes and p-values are not reported in the abstract.

An independent 2019 systematic review by Gwyer, Wragg, and Wilson in Cell and Tissue Research — notably authored outside the original Zagreb research group — examined BPC-157 in musculoskeletal soft tissue healing and reported uniformly positive preclinical findings. The authors also noted the critical limitation: no human data exists to confirm whether these effects translate to clinical outcomes in people.

Mechanisms proposed in the literature

Several cellular pathways have been proposed to explain BPC-157's preclinical effects. A 2011 mechanism paper by Chang and colleagues in Journal of Applied Physiology demonstrated that BPC-157 promotes tendon fibroblast outgrowth, supports fibroblast survival under oxidative stress, and facilitates cell migration through the FAK-paxillin signaling pathway — a pathway central to cell adhesion and movement. A subsequent 2014 paper by Chang and colleagues in Molecules showed that BPC-157, applied at 0.1–0.5 µg/mL in vitro, dose- and time-dependently upregulated growth hormone receptor expression at both mRNA and protein levels in cultured rat Achilles tendon fibroblasts — a mechanistic in vitro finding for which numeric fold-changes and p-values are not reported in the abstract.

A separate line of research concerns vascular biology. A 2014 review by Seiwerth and colleagues in Current Pharmaceutical Design summarized the preclinical vascular effects attributed to BPC-157 and framed the mechanistic hypotheses that subsequent studies have tested. A 2017 study by Hsieh and colleagues in Journal of Molecular Medicine reported that BPC-157, in chick chorioallantoic membrane, rat hind-limb ischemia, and HUVEC models, directionally increased vessel density, accelerated blood-flow recovery in ischemic muscle, and time-dependently activated the VEGFR2-Akt-eNOS signaling pathway via VEGFR2 internalization — a mechanistic preclinical finding for which numeric effect sizes are not reported in the abstract. A 2020 follow-up by Hsieh and colleagues in Scientific Reports reported, in isolated rat aorta and HUVEC models (n=3 independent experiments per condition), that BPC-157 at 1–100 µg/mL produced concentration-dependent, endothelium-dependent vasorelaxation that was fully abolished by NO-synthase inhibition (L-NAME) or NO scavenging (hemoglobin, p < 0.05), with mechanistic data showing enhanced Src, Cav-1, and eNOS phosphorylation and reduced Cav-1/eNOS binding. An editorial review by Sikiric and colleagues in World Journal of Gastroenterology in 2022 synthesized prior rat work on major vessel occlusion, Pringle-maneuver ischemia-reperfusion, and Budd-Chiari syndrome, framing collateral-vessel recruitment as a proposed mechanism by which BPC-157 may compensate for occluded flow — a narrative synthesis that does not itself report original effect sizes or p-values. The broader nitric oxide framework underpinning BPC-157 research has been reviewed by Sikiric and colleagues in Current Pharmaceutical Design in 2014.

Wound healing and gastrointestinal effects

BPC-157 research has also examined wound healing in skin and gut tissue. A 2015 study by Huang and colleagues in Drug Design, Development and Therapy used a rat alkali-burn model (n=10 per group) and HUVECs treated with BPC-157 at 200–800 ng/mL, reporting accelerated wound closure with enhanced granulation tissue, reepithelialization, and dermal remodeling by day 18, alongside increased endothelial migration and vascular tube formation in vitro via ERK1/2 phosphorylation — though the abstract does not report numeric % wound closure or p-values. A comprehensive 2021 review by Seiwerth and colleagues in Frontiers in Pharmacology surveyed BPC-157 across wound healing contexts including skin, cornea, muscle, tendon, and ligament. In gastrointestinal research, a 2017 rat colitis and ischemia-reperfusion study by Duzel and colleagues in World Journal of Gastroenterology reported that a single 10 µg/kg topical bath of BPC-157 to blood-deprived colon segments produced near-complete mucosal preservation by day 10, restored vessel-arcade interconnections, and normalized MDA and NO levels relative to saline controls — though the abstract does not report numeric % lesion reduction or p-values. A broader 2020 review by Sikiric and colleagues in Gut and Liver frames the compound's proposed GI activity within Robert's cytoprotection and organoprotection model — the longstanding physiological framework describing how the gastric mucosa protects itself against injury. The compound was also investigated as PL14736 in early-phase IBD clinical work, as described in a 2008 paper by Klicek and colleagues in Journal of Pharmacological Sciences, though that clinical program was never completed or approved.

Neurological and systemic effects in animal models

Preclinical research has examined BPC-157 beyond musculoskeletal tissue. A 2010 study by Tudor and colleagues in Regulatory Peptides reported that BPC-157 at 10 µg/kg or 10 ng/kg i.p., given 30 minutes before falling-weight traumatic brain injury in mice, directionally reduced unconsciousness and mortality across force impulses of 0.068–0.145 Ns, with the higher dose effective at the maximum 0.159 Ns impulse — though the abstract does not report numeric mortality percentages or p-values. A 2019 study by Perovic and colleagues in Journal of Orthopaedic Surgery and Research reported that a single i.p. dose of BPC-157 (200 µg/kg or 2 µg/kg) given 10 minutes after L2–L3 spinal-cord compression in Wistar rats produced progressive improvement in tail motor function with resolved spasticity by day 15, reduced white-matter vacuolization and axonal loss on histology by day 7, and lower motor-unit potentials on EMG (p < 0.025 vs. saline). A 2016 review by Sikiric and colleagues in Current Neuropharmacology framed BPC-157's effects within a brain-gut axis model, while a 2024 review by Sikiric and colleagues in Pharmaceuticals (Basel) examined the peptide's relationships with multiple neurotransmitter systems. The most recent synthesis, a 2025 review by Sikiric and colleagues in Pharmaceuticals (Basel), addresses BPC-157 as a modulator of angiogenesis and the nitric oxide system.

What the Human Evidence Looks Like

How many human studies exist

The 2025 systematic review by Vasireddi, Hahamyan, Salata, and colleagues in HSS Journal is the most rigorous available assessment of the BPC-157 literature (1993–2024) for orthopedic and sports medicine applications. Of 544 screened papers, the reviewers identified 36 studies meeting inclusion criteria — 35 preclinical and one human study. That single human study was a 12-patient retrospective case series of intra-articular BPC-157 injection for chronic knee pain, in which 7 of 12 patients (58%) reported self-described relief lasting more than 6 months. The report was uncontrolled, unblinded, not randomized, had no comparator arm, used patient-reported outcomes rather than validated pain instruments, and did not publish dose, effect size, confidence intervals, p-values, or systematically collected adverse events — limitations that severely constrain any clinical inference. As of April 2026, no completed, peer-reviewed Phase 2 or Phase 3 human efficacy trial for BPC-157 has been published in any indication. No peer-reviewed study has investigated pentadeca arginate as a distinct molecule under any conditions.

What that means for efficacy claims

The volume of preclinical BPC-157 literature is sometimes cited as evidence that the compound "works." It is important to understand what preclinical evidence does and does not establish. Rodent physiology differs from human physiology in ways that are often relevant to drug development. The majority of BPC-157 animal studies used direct injection into injury sites with sample sizes of 8-12 animals per group. A significant proportion of the published work comes from a single research group — the Zagreb laboratory associated with Sikiric and colleagues. Independent replication by groups not affiliated with the original researchers is limited. The animal data is scientifically interesting and may support future human investigation, but it cannot be extrapolated to confirm that BPC-157 or PDA produces the same effects in people.

Regulatory and Legal Status

FDA classification

As of April 2026, BPC-157 is a Category 2 bulk drug substance under FDA's framework for compounding under Section 503A. The FDA's Category 2 designation means the substance may present significant safety risks when used in compounding and is prohibited in compounded medications pending further evaluation. BPC-157 is not FDA-approved for any human therapeutic indication. The "PDA" counterion argument — that arginate salt formulation constitutes a distinct compound outside the Category 2 ruling — has not been validated by any FDA guidance as of this writing. Individuals and practitioners relying on that argument as a legal compliance pathway do so without FDA confirmation.

Sport ban status

BPC-157 was added to the World Anti-Doping Agency Prohibited List in 2022 under S0: Non-Approved Substances — the category for substances with no current approval by any governmental regulatory health authority. The U.S. Anti-Doping Agency has confirmed that BPC-157 is prohibited both in-competition and out-of-competition at all times. Because PDA shares the BPC-157 sequence, it inherits this prohibition status. Athletes subject to anti-doping testing should consult their sport's governing body before using any product labeled as PDA, pentadecapeptide, or BPC-157.

What this means practically

Products labeled as "PDA peptide" or "pentadeca arginate" sold through online vendors are not regulated by the FDA. The Operation Supplement Safety program maintained by the U.S. Department of Defense has confirmed that BPC-157 is a prohibited peptide and unapproved drug found in health and wellness products. Independent testing of peptide products sold as "research use only" has found contamination, dosing inconsistencies, and misidentified compounds. There is no legal pathway under current FDA policy to obtain pharmaceutical-grade BPC-157 or PDA for human use through compounding in the United States.

Pentadeca Arginate vs. BPC-157: Key Differences

This comparison is for scientific context only. These compounds have fundamentally different marketing claims than their actual molecular relationship warrants, and neither has an established evidence base from human clinical trials.

BPC-157 and pentadeca arginate share the same 15-amino-acid sequence (GEPPPGKPADDAGLV). The proposed distinction is the salt counterion: acetate in conventional BPC-157, arginine in PDA. This is a formulation chemistry difference, not a sequence difference. The biological activity attributed to BPC-157 in preclinical literature derives from the peptide sequence itself — not the counterion. Whether a different salt form produces meaningfully different bioavailability, stability, or efficacy in humans has not been studied in any peer-reviewed setting.

The marketing narrative that PDA is a "legal alternative" to BPC-157 rests on the unsupported argument that the FDA's Category 2 classification does not cover arginate salt variants. Practitioners and consumers should not assume legal compliance based on vendor marketing materials alone.

Safety: What Is and Is Not Known

Animal safety data

A 2020 preclinical safety evaluation by Xu and colleagues in Regulatory Toxicology and Pharmacology examined BPC-157 across multiple species — mice, rats, rabbits, and dogs — and reported no serious toxicity, no genotoxicity, and no embryotoxicity at doses evaluated. A 2011 study by Ilic and colleagues in Life Sciences reported that BPC-157 at 10 µg/kg or 10 ng/kg i.p. (or 0.16 µg/mL per-oral) given concurrently with 12.5 mg/kg/day diclofenac in Wistar rats directionally counteracted diclofenac-induced gastric, intestinal, and hepatic lesions and reduced elevations in bilirubin, AST, and ALT — though the abstract does not report numeric magnitudes or p-values. This animal safety profile is encouraging, but animal safety data does not establish that a compound is safe in humans. The metabolic and pharmacokinetic differences between species are relevant, and Phase 1 human safety trials have not been completed for BPC-157.

Absence of clinical safety data

No Phase 1 clinical safety trial for BPC-157 has been completed and published. No Phase 1 or Phase 2 trial has been conducted for PDA as a distinct compound. The human safety profile of either substance is unknown. This is not a minor gap. It means there is no established data on how these peptides behave in human pharmacokinetics, what adverse events occur at what frequencies, or what drug interactions are possible. Claims that either compound is "safe for human use" are not supported by adequate clinical evidence.

Risks from unregulated sources

Products sold online as PDA or BPC-157 for "research purposes" fall outside FDA manufacturing oversight. Contamination with microbial endotoxins, incorrect peptide concentrations, and mislabeled compounds have been documented in independently tested peptide products. Injection of unverified, unsterile compounds carries infection and inflammatory risks that are independent of any effects the peptide itself might or might not have.

Who Should Not Use This Compound

Based on the proposed mechanisms from preclinical research, the following groups face elevated theoretical risk. This is not a clinical safety profile derived from human trials — human safety data does not exist.

• Individuals with active or suspected cancer: BPC-157's proposed angiogenesis-promoting mechanism, particularly via VEGFR2 signaling, could theoretically support tumor vascularization. Anyone with a history of or active malignancy should not use compounds with pro-angiogenic preclinical findings without oncologist input.
• Pregnant or breastfeeding individuals: No safety data exists for these populations. Use during pregnancy or lactation is contraindicated on the basis of absent safety data alone.
• Competitive athletes subject to anti-doping testing: BPC-157 is prohibited by WADA under S0 both in-competition and out-of-competition. PDA, sharing the BPC-157 sequence, inherits this prohibition.
• Individuals with known peptide hypersensitivity or a history of serious peptide-related adverse reactions.
• Individuals who would be relying solely on vendor-supplied, non-pharmaceutical-grade products: the absence of manufacturing oversight creates risks beyond the peptide's inherent biological profile.

Which Biomarkers Are Relevant if You Are Exploring Peptide Science?

The tissue repair and anti-inflammatory mechanisms proposed for BPC-157 and PDA are traceable to measurable biological markers. Understanding your baseline on these markers provides objective context — regardless of which compounds or interventions someone is considering.

• High-sensitivity C-reactive protein (hs-CRP): A systemic marker of low-grade inflammation. BPC-157's proposed anti-inflammatory mechanism is central to its preclinical profile; establishing a baseline hs-CRP level provides a reference point for understanding the inflammatory state someone is starting from.
• ALT (alanine aminotransferase): A marker of hepatocyte integrity. Before evaluating any investigational compound, understanding baseline liver enzyme status establishes whether liver function is within normal parameters.
• eGFR (estimated glomerular filtration rate): A marker of kidney filtration function. Baseline renal function matters when evaluating any compound cleared by the kidneys, and is a standard part of any comprehensive pre-intervention assessment.
• Creatinine: Works alongside eGFR to characterize kidney function. Both are standard safety markers in any thorough metabolic baseline panel.
• Complete blood count (CBC): Establishes red and white cell indices and platelet counts. Provides baseline data relevant to inflammation, immune status, and overall systemic health before any new compound exposure.
• Comprehensive metabolic panel: Covers glucose regulation, electrolyte balance, liver and kidney function in an integrated snapshot. A broad metabolic baseline is the appropriate starting point for anyone interested in evaluating any investigational compound's potential effects on their biology over time.

When to Take This Seriously

If you are experiencing tendon pain, slow recovery from injury, gut symptoms, or persistent inflammation, those are real clinical problems with established FDA-approved diagnostic and therapeutic pathways. A sports medicine physician, orthopedist, gastroenterologist, or primary care provider can evaluate the underlying cause. Inflammatory markers, metabolic panels, and organ function testing provide objective, interpretable data about what is actually driving those symptoms. That information is more clinically useful than any preclinical peptide literature — and it is available now, without waiting for human trial results that do not yet exist.

That commitment to data before decisions is what drives Superpower's approach to preventive health: the belief that understanding your biology through objective measurement is the foundation for every health decision, whether you are evaluating established therapies or following emerging preclinical research.

IMPORTANT SAFETY INFORMATION

Pentadeca arginate (PDA) and BPC-157 are not FDA-approved for any indication. BPC-157 is classified as a Category 2 bulk drug substance as of April 2026, prohibited in compounding under FDA Sections 503A and 503B. PDA, sharing the BPC-157 amino acid sequence, is not separately classified by the FDA and does not have an independent regulatory approval pathway. Superpower is a technology platform. Superpower does not prescribe or dispense medications, and does not facilitate access to BPC-157 or PDA.

No clinical safety profile for BPC-157 or PDA in humans has been established through completed Phase 1 trials. All safety data derives from animal studies. Human pharmacokinetics, adverse event frequencies, and drug interactions are unknown.

Contraindications (based on proposed preclinical mechanisms): active or suspected malignancy (pro-angiogenic preclinical profile); pregnancy or breastfeeding (no safety data); athletes subject to WADA anti-doping rules (BPC-157 prohibited under S0, in-competition and out-of-competition).

Warnings: products sold as PDA or BPC-157 through online vendors are not manufactured under FDA oversight; contamination, incorrect dosing, and mislabeled compounds have been documented in independently tested peptide products; injection of non-pharmaceutical-grade compounds carries infection and inflammatory risks; the "PDA counterion argument" for regulatory compliance has not been validated by FDA guidance as of April 2026.

Long-term safety data: not available for any duration or route of administration in humans. The absence of published safety concerns in animal studies does not establish an acceptable human risk profile.

WADA status: As of the 2026 WADA Prohibited List, BPC-157 is classified under S0: Non-Approved Substances, prohibited in-competition and out-of-competition at all times. PDA inherits this prohibition as a BPC-157 sequence variant.

This is not a complete summary of risks. No FDA-approved prescribing information exists for these compounds. Regulatory updates should be verified at FDA.gov.

Additional Questions

Can a doctor prescribe BPC-157 or PDA?

No legal prescribing pathway currently exists. BPC-157's Category 2 FDA classification prohibits its use in compounded medications under Sections 503A and 503B. It is not an FDA-approved drug with a prescribing label. A physician cannot legally prescribe a compound for which no lawful pharmaceutical preparation exists under current FDA policy.

Is there any human safety data for PDA or BPC-157?

No completed Phase 1 clinical safety trial has been published for either compound. Animal studies — including a 2020 multi-species evaluation by Xu and colleagues — found no serious toxicity, genotoxicity, or embryotoxicity at doses evaluated. However, animal safety data does not establish human safety. The human pharmacokinetic and adverse event profile of BPC-157 and PDA remains unknown.

What is the BPC-157 FDA Category 2 classification?

The FDA's Category 2 designation identifies bulk drug substances that may present significant safety risks when used in compounding under Section 503A. It prohibits those substances from being used in compounded medications. BPC-157 received this designation in November 2023. Category 2 is distinct from Category 3 (which indicates known serious safety risks) — it signals that the safety data is insufficient to support compounding, not that the compound has been demonstrated harmful. The classification nonetheless removes the legal compounding pathway that had previously been used to access BPC-157 in the United States.